Genomes and Genes
Summary: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Publications268 found, 100 shown here
- Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage IIC Riccioni
Complex Unit of Angiology, Nuovo Regina Margherita Hospital, Rome, Italy
Int Angiol 27:253-9. 2008..PLC is involved in cellular metabolism and is transformed into two active substances, free L-carnitine and propionyl-coenzyme A in the mitochondria, which take part in fatty acid transfer and in the citric acid cycle, respectively...
- European guidelines on cardiovascular disease prevention in clinical practice: executive summaryIan Graham
Department of Cardiology, The Adelaide and Meath Hospital, Dublin, Ireland
Eur Heart J 28:2375-414. 2007
- Eplerenone in patients with systolic heart failure and mild symptomsFaiez Zannad
INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
N Engl J Med 364:11-21. 2011..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
- Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trialsGiorgia De Berardis
Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8 A, 66030 S Maria Imbaro, Italy
BMJ 339:b4531. 2009..To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease...
- Drug-eluting stent fracture: incidence, contributing factors, and clinical implicationsTimothy Canan
Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, California, USA
Catheter Cardiovasc Interv 75:237-45. 2010..Other complications observed with stent fracture include stent thrombosis, coronary aneurysms, myocardial infarction, and sudden death...
- Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) TrialBruce L Wilkoff
The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F 15, Cleveland, OH 44195, USA
JAMA 288:3115-23. 2002..Most currently implanted ICD devices provide dual-chamber pacing therapy. The most common comorbid cause for mortality in this population is congestive heart failure...
- Treatment of patent ductus arteriosusJonathan Wyllie
The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK
Semin Neonatol 8:425-32. 2003..PDA closure can then be achieved using medical means, with surgery reserved for patients in whom this fails or in whom there are contra-indications. However, the optimum timing for intervention remains unknown...
- ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise thJeffrey L Anderson
J Am Coll Cardiol 50:e1-e157. 2007
- Ranolazine: a review of its use in chronic stable angina pectorisM Asif A Siddiqui
Adis International Limited, Auckland, New Zealand
Drugs 66:693-710. 2006..Nevertheless, ranolazine ER may well prove to be a useful alternative and adjunct to conventional haemodynamic antianginal therapy in the treatment of chronic stable angina...
- Pharmacological activity of cardiovascular agents from herbal medicineJohn W Ho
Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
Cardiovasc Hematol Agents Med Chem 5:273-7. 2007..The study will provide insights into drug action and demonstrate the therapeutic benefits of herbal medicine for the treatment of cardiovascular disease...
- Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort studyStefan Störk
Department of Internal Medicine I Center for Cardiovascular Medicine, University of Wurzburg, Klinikstrasse 6 8, D 97070 Wurzburg, Germany
Eur J Heart Fail 10:1236-45. 2008..The effectiveness of chronic heart failure (CHF) pharmacotherapy in unselected cohorts is unknown...
- Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomographyRory Hachamovitch
Department of Imaging, Cedars-Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, Calif 90048, USA
Circulation 107:2900-7. 2003..These findings have significant consequences for future approaches to post-single photon emission computed tomography patient management if confirmed by prospective evaluations...
- Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive diseaseClaudio Allegra
San Giovanni Hospital, Rome, Italy
Ann Vasc Surg 22:552-8. 2008..From these preliminary data has emerged an indication of therapy with PLC for chronic obstructive arteriopathy of the lower limbs at stage II. Further studies with higher numbers of patients and more controlled variables are planned...
- Methods for identifying cardiovascular agents: a reviewDavid Anthony Tulis
Cardiovascular Disease Research Program, J L Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA
Recent Pat Cardiovasc Drug Discov 1:47-56. 2006..The invention disclosed in Methods for identifying cardiovascular agents  provides screening methods which can be used to identify certain suspected cardiovascular agents that ..
- Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) studyChiara Melloni
Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
Expert Rev Cardiovasc Ther 6:9-16. 2008....
- Telmisartan prevents cardiovascular events in a broad group of at-risk patientsMagnus Baumhakel
University Hospital of the Saarland, Department of Cardiology, Homburg Saar, Germany
Expert Opin Pharmacother 10:3113-7. 2009..In these patients who are intolerant to ACE-Is or who do not achieve blood pressure control, the ARB with the best evidence for secondary prevention is telmisartan according to the results of the ONTARGET trial...
- Systems biology approaches to the study of cardiovascular drugsYuri Nikolsky
GeneGo, Inc, St Joseph, MI, USA
Methods Mol Biol 662:221-43. 2010..All relevant steps, for example, experimental design, tissue collection and high quality RNA preparation, bioinformatical analysis of functional processes, and pathways (targeted and untargeted) are addressed...
- Ranolazine (Ranexa) in the treatment of chronic stable anginaSajid Aslam
Division of Cardiovascular Medicine, University Hospital, Nottingham, UK
Adv Ther 27:193-201. 2010..This review provides an insight into this treatment option, describes the clinical trials evidence, proposed mechanism of action, and pharmacokinetics, and outlines the indications for its use in chronic stable angina...
- ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999Elliott M Antman
Circulation 110:588-636. 2004
- The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatmentM Komajda
Eur Heart J 24:464-74. 2003..The survey also identifies several important factors including age, gender, type of hospital ward, co morbid factors which influence the prescription of heart failure medication at discharge...
- Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patientsAli Hamaad
University Department of Medicine, City Hospital, Dudley Road, Birmingham, England, UK
Cardiovasc Drugs Ther 20:359-64. 2006..CONCLUSIONS: Three month supplementation of omega 3 PUFA (Omacor) 1 g/day has no effect on HRV is patients post AMI...
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of CardiologyKarl Swedberg
, Department of Medicine, Sahlgrenska University Hospital, Sweden
Eur Heart J 26:1115-40. 2005
- Neuropsychiatric effects of cardiovascular drug therapySeth Keller
Department of Medicine, Division of Cardiology, Beth Israel Medical Center, New York, New York 10595, USA
Cardiol Rev 11:73-93. 2003..Since neuropsychiatric symptoms are seen in patients with cardiovascular disease, clinicians should be aware of the possible relationship between these symptoms and concurrent cardiovascular drug therapy...
- Antianginal efficacy of omapatrilat in patients with chronic angina pectorisBernard R Chaitman
Saint Louis University School of Medicine, St Louis, Missouri 63117, USA
Am J Cardiol 95:1283-9. 2005..The data confirm the proof of principle that broader vasopeptidase inhibition beyond angiotensin-converting enzyme inhibition is required to alleviate symptoms of chronic angina...
- Adherence in heart failure in the elderly: problem and possible solutionsMartje H L van der Wal
Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
Int J Cardiol 125:203-8. 2008..Non-adherence to this regimen is a problem in many heart failure patients, leading to worsening symptoms, rehospitalization and decreased quality of life...
- 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develTheodore D Fraker
J Am Coll Cardiol 50:2264-74. 2007
- Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapyRisto S Cvetkovic
Adis International Limited, Auckland, New Zealand
Drugs 65:1005-24. 2005..01). Dexrazoxane is the only cardioprotective agent with proven efficacy in cancer patients receiving anthracycline chemotherapy and is a valuable option for the prevention of cardiotoxicity in this patient population...
- Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trialDavid A Morrow
TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
JAMA 297:1775-83. 2007..Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS)...
- Does ranolazine have a place in the treatment of acute coronary syndromes?L Kristin Newby
JAMA 297:1823-5. 2007
- Neuropsychiatric consequences of cardiovascular medicationsJeff C Huffman
Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
Dialogues Clin Neurosci 9:29-45. 2007The use of cardiovascular medications can have a variety of neuropsychiatric consequences. Many cardiovascular agents cause higher rates of fatigue and sedation than placebo, and case reports of medication-induced mood syndromes, ..
- The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemiaSteven E Lipshultz
Department of Pediatrics, University of Miami School of Medicine, Holtz Children s Hospital of the University of Miami Jackson Memorial Medical Center and the Sylvester Comprehensive Cancer Center, Miami 33101, USA
N Engl J Med 351:145-53. 2004..Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells. Dexrazoxane, a free-radical scavenger, may protect the heart from doxorubicin-associated damage...
- Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exerciseRobinson Joannides
Department of Pharmacology, Rouen University Hospital, INSERM U644, Rouen, France
Br J Clin Pharmacol 61:127-37. 2006....
- Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetesCaroline Sirois
Faculty of Pharmacy, Laval University, Quebec, Canada
Diabetes Care 30:1880-2. 2007
- Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task ForceJohn McB Hodgson
St. Joseph's Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013, USA
Catheter Cardiovasc Interv 69:327-33. 2007
- The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of StabCaroline A Daly
Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
Eur Heart J 26:1011-22. 2005....
- NO/redox disequilibrium in the failing heart and cardiovascular systemJoshua M Hare
Johns Hopkins University School of Medicine, Department of Medicine, Cardiology Division, Baltimore, Maryland 21205, USA
J Clin Invest 115:509-17. 2005....
- Ranolazine and other antianginal therapies in the era of the drug-eluting stentPeter Berger
JAMA 291:365-7. 2004
- Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trialBernard R Chaitman
Department of Medicine, Division of Cardiology, St Louis University School of Medicine, St Louis, MO, USA
JAMA 291:309-16. 2004....
- Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?Gabor T Kovacs
Haemato oncology Division, 2nd Department of Pediatrics, Semmelweis University, Tuzolto 7 9, 1094, Budapest, Hungary
Eur J Pediatr 166:1187-8. 2007
- Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarctionEric Bates
Duke Clinical Research Institute, 2400 Pratt St, Room 7035, Durham, NC 27705
Circulation 117:886-96. 2008..KAI-9803, a delta-protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI)...
- Time dependent vascular and myocardial responses of a second generation, small vessel, paclitaxel-eluting stent platformCraig A Thompson
Cardiology Section, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
Catheter Cardiovasc Interv 73:597-604. 2009..The purpose of this study was to evaluate the time-dependent vascular and myocardial responses to a second-generation, small vessel (< or =2.5 mm) paclitaxel-eluting stent (PES) platform...
- Metabolic manipulation in ischaemic heart disease, a novel approach to treatmentLeong Lee
Wales Heart Research Institute, Heath Park, Cardiff, CF14 4XN, UK
Eur Heart J 25:634-41. 2004..They offer significant promise for the treatment of symptoms occurring due to inoperable aortic stenosis, hypertrophic cardiomyopathy, and chronic heart failure...
- Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overviewLouis J Ignarro
Nitric Oxide Research Group, Molecular and Medical Pharmacology, Center for the Health Sciences, University of California, Los Angeles, USA
Circ Res 90:21-8. 2002..Here, we review these classes of agents, summarizing their fundamental chemistry and pharmacology, and provide an overview of their cardiovascular mechanisms of action...
- Fibrates and future PPARalpha agonists in the treatment of cardiovascular diseaseBart Staels
Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France
Nat Clin Pract Cardiovasc Med 5:542-53. 2008....
- The challenge of polypharmacy in cardiovascular medicineMassimo Volpe
Cardiology Department, IInd School of Medicine, University of Rome Sapienza, S Andrea Hospital, Rome, Italy
Fundam Clin Pharmacol 24:9-17. 2010..However, large randomized trials are required to define its impact on clinical outcomes. This review will focus on challenges of polypharmacy in CV medicine, illustrating potential options to face this emerging crisis...
- Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programmeJohn M Lasala
Washington University School of Medicine, St Louis, MO 63110, USA
EuroIntervention 5:67-77. 2009..We report 2-year outcomes in a large unselected drug-eluting stent population (N=7,492) in the TAXUS Express2 ARRIVE post-market surveillance programme (101 U.S. sites)...
- Aspirin for prevention of cardiovascular eventsWilliam R Hiatt
BMJ 337:a1806. 2008
- Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trialJean Claude Tardif
Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada
Eur Heart J 30:540-8. 2009..To evaluate the anti-anginal and anti-ischaemic efficacy of the selective I(f) current inhibitor ivabradine in patients with chronic stable angina pectoris receiving beta-blocker therapy...
- Loss of cardioprotection with ageingKerstin Boengler
Institut fur Pathophysiologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany
Cardiovasc Res 83:247-61. 2009..g. ischaemic pre and postconditioning in aged organs and animals will be discussed, and the development of strategies aimed to antagonize the age-induced loss of protection will be addressed...
- Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease?Andrew J Krentz
Institute of Developmental Sciences, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK
J Vasc Res 46:515-26. 2009..The hypothesis that vascular events can be prevented, or at least deferred, through earlier therapeutic intervention in pre-diabetic subjects with glucose intolerance is amenable to testing in clinical trials...
- New strategies for improving heart failure management: a primary care perspectiveJ Basile
Primary Care Division, Ralph H Johnson VA Medical Center, Charleston, SC 29403, USA
South Med J 94:166-74. 2001..Digoxin may be added to therapy for patients with persistent symptoms or rapid atrial fibrillation. Clinical trials have shown that such combination regimens reduce the risk of hospitalization and death in patients with heart failure...
- Metabolic therapeutics in angina pectoris: history revisited with perhexilineSally Inglis
Faculty of Health Sciences, University of Queensland, Australia
Eur J Cardiovasc Nurs 5:175-84. 2006..This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir...
- Atrial fibrillation and dementia in a population-based study. The Rotterdam StudyA Ott
Department of Epidemiology and Biostatistics, Erasmus University Medical School, Rotterdam, The Netherlands
Stroke 28:316-21. 1997..We investigated the association of atrial fibrillation with dementia and cognitive impairment in a large cross-sectional, population-based study in the elderly...
- Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatmentLeong Lee
Department of Cardiology, University of Nottingham, Queens Medical Centre, Nottingham, England
Circulation 112:3280-8. 2005..Perhexiline may therefore represent a novel treatment for CHF with a good safety profile, provided that the dosage is adjusted according to plasma levels...
- Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-upLubomir Elbl
Department of Cardiopulmonary Testing, University Hospital Brno, Jihlavska 20, Brno, 62500, Czech Republic
Support Care Cancer 14:128-36. 2006..The authors conducted a retrospective study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for hematological malignancy...
- Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of CardiologyFrans Van de Werf
Cardiology, Gasthuisberg University Hospital, Leuven, Belgium
Eur Heart J 24:28-66. 2003
- Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patientsLubomir Elbl
Department of Cardiology, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic
Eur J Pediatr 164:678-84. 2005..CONCLUSION: Dexrazoxane seems to reduce the risk of late subclinical cardiotoxicity. Dexrazoxane-treated patients revealed better exercise tolerance; however the haemodynamic response to the stress was no different in both sub-groups...
- Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis?Fareed Shaikh
Cardiovascular Disease Section, Aurora Sinai Aurora St Luke s Medical Centers, University of Wisconsin School of Medicine and Public Health Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA
Catheter Cardiovasc Interv 71:614-8. 2008..The predictors and clinical significance for stent fracture (SF) in drug-eluting stents (DES) remain unknown. We identified procedural factors leading to SF and its clinical consequences in DES...
- Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolutionA R Sielecki
Department of Biochemistry, University of Alberta, Edmonton, Canada
Science 243:1346-51. 1989..Knowledge of the actual structure, as opposed to the use of models based on related enzymes, should facilitate the design of renin inhibitors...
- Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of CardiologyMichel Ovize
Service d Explorations Fonctionnelles Cardiovasculaires and Inserm U886, Hospices Civils de Lyon, University of Lyon, France
Cardiovasc Res 87:406-23. 2010....
- Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazineMarkus Jerling
Clinical Pharmacology, CV Therapeutics, Palo Alto, CA, USA
Clin Pharmacol Ther 78:288-97. 2005..No serious adverse events were observed in the study...
- Management of heart failure in primary health care. A retrospective study on electronic patient records in a registered populationGunnar Nilsson
Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden
Scand J Prim Health Care 20:161-5. 2002..To study the prevalence, patient characteristics and management of patients with heart failure, and the feasibility of using everyday electronic patient records for research...
- Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable anginaJean Claude Tardif
Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
Eur Heart J 26:2529-36. 2005..Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol...
- Long-term outcomes of bifurcation lesions after implantation of drug-eluting stents with the "mini-crush technique"Alfredo R Galassi
Department of Internal Medicine and Systemic Disease, Clinical Division of Cardiology, Ferrarotto Hospital, University of Catania, Italy
Catheter Cardiovasc Interv 69:976-83. 2007..To evaluate clinical and angiographic long-term outcome of "the mini-crush" technique for treating bifurcation lesions...
- Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery diseaseWhady Hueb
Heart Institute of the University of Sao Paulo, Sao Paulo, Brazil
Circulation 115:1082-9. 2007....
- Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stentsJürgen Pache
Deutsches Herzzentrum, Lazarettstr 36, 80636 München, Germany
Catheter Cardiovasc Interv 68:690-5. 2006..To study the 5-year outcome of patients treated with gold-coated stent placement...
- Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteriesCheol Whan Lee
Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
Catheter Cardiovasc Interv 69:821-5. 2007..Predictors of cardiac events and restenosis after sirolimus-eluting stent (SES) implantation in small coronary arteries were evaluated...
- [Interactions between cardiovascular drugs and anesthesia and surgery]Pierre Albaladejo
Service d Anesthésie Réanimation SAMU SMUR 94, Hopital Henri Mondor, Creteil
Presse Med 35:1697-702. 2006..Interruption of antiplatelet agents appears to be associated with a risk of arterial thrombosis in patients with coronary conditions, notably those with conventional stents and most especially those with drug-eluting stents...
- Improved survival with drug-eluting stent implantation in comparison with bare metal stent in patients with severe left ventricular dysfunctionGiuseppe Gioia
Atlantic City Medical Center, Pomona, New Jersey 08240, USA
Catheter Cardiovasc Interv 68:392-8. 2006....
- [Drugs used in cardiovascular diseases and cytokines]Dariusz Andrzejczak
Z Zakładu Farmakodynamiki Uniwersytetu Medycznego w Lodzi
Wiad Lek 59:232-7. 2006..In the paper the influence of statins, fibrates, angiotensin converting enzyme inhibitors (ACEI), beta-blockers, calcium channel blockers and phosphodiesterase inhibitors on the activity of cytokines was introduced...
- Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registryJohn A Spertus
MPH, Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111
Circulation 113:2803-9. 2006..The rate and consequences of prematurely discontinuing thienopyridine therapy after DES placement for acute myocardial infarction (MI) are unknown...
- Practical algorithms for pharmacologic management of the post myocardial infarction patientJames A Reiffel
Cardiology Division, Department of Medicine, Columbia University, New York, New York, USA
Clin Cardiol 28:I28-37. 2005..Current guidelines also recommend that patients post MI with elevated cholesterol levels should be prescribed lipid therapy with a statin at hospital discharge...
- Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapyJonathan Sackner-Bernstein
Clin Cardiol 28:I19-27. 2005....
- Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stentsGaku Nakazawa
Division of Cardiology, Mitsui Memorial Hospital, Chiyoda ku, Tokyo, Japan
Catheter Cardiovasc Interv 69:808-14. 2007..Sirolimus-eluting stents (SES) have been demonstrated to reduce restenosis. However, there have been few studies evaluating the impact of renal insufficiency on the angiographic as well as clinical outcomes after SES implantation...
- Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularizationPaolo Ortolani
Institute of Cardiology, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Catheter Cardiovasc Interv 69:790-8. 2007..To see whether use of a sirolimus-eluting stent (SES) is superior to a third-generation thin-strut, cobalt-chromium stent (CCS) in terms of in-segment late loss at 9 months in patients with symptomatic coronary artery disease...
- Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) studyRichard B Devereux
Greenberg Division of Cardiology, Weill Medical College of Cornell University, New York, NY 10021, USA
Curr Med Res Opin 23:443-57. 2007....
- Restenosis following thin-strut bare-metal stents versus thick-strut drug-eluting stentsDavid J Moliterno
Catheter Cardiovasc Interv 69:799-800. 2007
- Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsetsProbal Roy
Division of Cardiology, Washington Hospital Center, Washington DC 20010, USA
Catheter Cardiovasc Interv 70:167-72. 2007..The data for more complex subsets of patients and lesions remains conflicting. This study aimed to compare SES with PES in a selected population with a broad range of complex features...
- Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stentsCheol Whan Lee
Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
Catheter Cardiovasc Interv 71:594-8. 2008..Sirolimus-eluting stents have been increasingly used for treatment of restenosis after implantation of bare metal stents (BMSs) or drug-eluting stents (DESs), but little is known regarding their long-term outcomes...
- Treatment of drug-eluting stent restenosis: a sandwich may not be the best comboJorge Belardi
Catheter Cardiovasc Interv 71:599. 2008
- Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?Fen Wei Wang
Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
Catheter Cardiovasc Interv 71:636-43. 2008..We evaluated mortality in the first year after implantation of DES, specifically the sirolimus-eluting stent (SES), Cypher vs. BMS in "real world" older patients using the Medicare claims database...
- DES editorial. Is there a survival benefit?Dr Martyn Thomas
Catheter Cardiovasc Interv 71:644-5. 2008
- Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysisSoko Setoguchi
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
J Am Coll Cardiol 51:1247-54. 2008..We sought to assess the relationship between increasing use of cardiovascular medications and trends in long-term prognosis after myocardial infarction (MI) in the elderly...
- Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heartMatteo Anselmino
University Department of Cardiology, San Giovanni Battista Molinette Hospital, Turin, Italy
Eur J Cardiovasc Prev Rehabil 15:216-23. 2008..This report compares the impact of EBM and revascularization on mortality and cardiovascular events (CVE=mortality, myocardial infarction or stroke) in CAD patients with and without DM...
- Stenting for unprotected left main coronary artery stenosis: a further stepY Cottin
Arch Cardiovasc Dis 101:7-8. 2008
- Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients)R Cherradi
Fédération de cardiologie, Pôle cardiovasculaire et métabolique, CHU Rangueil, Toulouse, France
Arch Cardiovasc Dis 101:11-7. 2008..After coronary stenting with drug eluting stents, long-term clinical outcome of unprotected left main coronary artery disease is unknown, even large scale registries or randomised trials with coronary artery bypass graft are ongoing...
- Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft diseaseRavi K Ramana
Division of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA
Catheter Cardiovasc Interv 71:886-93. 2008..Specifically, we compared clinical endpoints of patients who received sirolimus-eluting stents (SES) versus bare-metal stents (BMS) for SVG disease...
- Drug-eluting stent in saphenous vein graft lesionsRan Kornowski
Catheter Cardiovasc Interv 71:894-5. 2008
- The role of percutaneous revascularization for renal artery stenosisGregory J Dubel
Department of Diagnostic Imaging, Brown University Medical School, Division of Interventional Radiology, Providence, Rhode Island 02903, USA
Vasc Med 13:141-56. 2008..Until the CORAL trial results are in, physicians will continue to be faced with difficult choices when determining the optimal management for RAS patients and deciding which, if any, patients should be offered revascularization...
- Does the preventive effect of different drugs depend on location of the atherosclerotic process?P Poredos
Department of Vascular Diseases, University Medical Center Ljubljana, Slovenia
Int Angiol 27:274-80. 2008....
- Highlights of the 56th annual scientific session of the American College of CardiologyX Rabasseda
Prous Science Medical Information Department, Prous Science
Timely Top Med Cardiovasc Dis 11:E12. 2007
- Cardiovascular protection paradigms: is change on the horizon?Vasilios Papademetriou
Department of Veterans Affairs and Georgetown University Medical Centers, Washington, DC, USA
Rev Cardiovasc Med 8:200-13. 2007..Such changes should be considered in the design of new clinical trials and in the interpretation of current data...
- Late medical versus interventional therapy for stable ST-segment elevation myocardial infarctionSammy Elmariah
Mount Sinai Medical Center, New York, NY, USA
Nat Clin Pract Cardiovasc Med 5:42-52. 2008....
- Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantationYoung Hoon Jeong
Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388 1 Poongnap dong, Songpa Gu, Seoul, 138 736, Republic of Korea
Int J Cardiol 125:36-40. 2008..Whether drug-eluting stents (DES) can reduce long-term clinical events in CKD patients compared with bare metal stents (BMS) has not been established...
- Medical management of abdominal aortic aneurysmJ Golledge
Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia 4811
Eur J Vasc Endovasc Surg 34:267-73. 2007..Medical management also is required to reduce peri-operative risks and stabilise endovascular aneurysm repair. Whilst some of the therapies targeting cardiovascular risk reduction may be helpful, other emerging strategies are discussed...
- Treatment of unprotected left main disease with drug-eluting stents in patients at high risk for coronary artery bypass graftingPeter Barlis
Department of Cardiology, Austin Hospital, Melbourne, Victoria 3084, Australia
Cardiovasc Revasc Med 8:84-9. 2007..Recently, drug-eluting stents (DES) have reduced instent restenosis after PCI, but their role in the treatment of left main disease remains unclear...
- Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarctionL Iri Kupferwasser
Division of Cardiology, Cedars Sinai Medical Center, University of California, Los Angeles School of Medicine, California 90048, USA
Catheter Cardiovasc Interv 70:1-8. 2007..The aim of this study was to compare the procedural characteristics and outcomes of patients with acute myocardial infarction treated with drug-eluting stents (DES) vs. bare metal stents (BMS)...
- Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass graftingGiuseppe Gioia
Atlantic City Medical Center, Pomona, NJ 08240, USA
Catheter Cardiovasc Interv 70:26-33. 2007....
- Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trialAlexandre Berger
Service of Cardiology, Clinic Cecil, Lausanne, Switzerland
Catheter Cardiovasc Interv 70:163-6. 2007..Analysis of the 3-year outcome of the original population of the TAXi trial which compared the efficacy of the paclitaxel (PES) and the sirolimus (SES) stents in a randomized "real world" investigation...
- Incidence and predictors of clinically driven target lesion revascularization from bare-metal stents to drug-eluting stentsSeung-Jung Park
Catheter Cardiovasc Interv 70:184. 2007
- Pharmacological interventions for peripheral artery diseaseDaniel A Duprez
University of Minnesota, Cardiovascular Division, Medical School, VCRC Room 270, Minneapolis, MN 55455, USA
Expert Opin Pharmacother 8:1465-77. 2007..New developments should focus on improvement of endothelial function, vascular repair and enhancement of collateral circulation...
- Organic Nitrate Metabolism, Tolerance and ActionHo Leung Fung; Fiscal Year: 2010..believe that our studies can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use ..
- Pharmacogenetics and Cardiovascular EventsBruce Psaty; Fiscal Year: 2006..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
- Impact of Medicaid Policy on cardiovascular drug use and clinical outcomesMichael A Fischer; Fiscal Year: 2010....
- Organic Nitrate Metabolism, Tolerance and ActionHo Leung Fung; Fiscal Year: 2007..We believe that our studies can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use ..
- Atrial natriuretic peptide receptor crystallizationFocco van den Akker; Fiscal Year: 2004..Our long term structural studies on the molecular mechanism of ANP receptor signaling could enhance the development of renal and cardiovascular drugs. ..
- Coupling mechanisms of OP4 receptor and calcium channelsVictor Ruiz Velasco; Fiscal Year: 2006..to clarify the signaling mechanisms underlying these processes and facilitate the development of novel cardiovascular agents for treating hypertension resulting from increased sympathetic tone...
- eNOS Polymorphisms, Aging and Platelet FunctionJane Freedman; Fiscal Year: 2005..We have continued to examine the imoortance of this mutation to the vascular response. ..
- Inhibitors of PAR1-G13 Interface for ArthersclerosisAnnette Gilchrist; Fiscal Year: 2002..Hundreds of billions of dollars are spent each year treating heart disease. In 1998, it was estimated that sales of cardiovascular drugs alone were $37 billion. ..
- Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer SurvivorsSteven Lipshultz; Fiscal Year: 2007..If the HFE mutations are related to increased cardiotoxicity of anthracyclines. This study will elucidate the molecular mechanisms of anthracycline cardiotoxicity in pediatric ALL cancer survivors. ..
- PEDIATRIC CARDIOMYOPATHY REGISTRYSteven Lipshultz; Fiscal Year: 2000..The registry should lead to definitive understanding of the pathogenesis of these disorders and offer the hope to have a major clinical impact on the clinical practice of medicine in this area. ..
- PEDIATRIC CARDIOMYOPATHY REGISTRYSteven Lipshultz; Fiscal Year: 2007..These studies will dramatically increase our understanding of pediatric cardiomyopathy, suggest new areas of research and improved patient management. ..
- HAART Associated Cardiotoxicity in HIV-Infected ChildrenSteven Lipshultz; Fiscal Year: 2007..The findings will help determine the need for cardiovascular follow-up, prevention and therapeutic trials. ..
- PEDIATRIC CARDIOMYOPATHY REGISTRYSteven Lipshultz; Fiscal Year: 2003..abstract_text> ..
- Plasminogen activators and NMDA after brain injuryWilliam Armstead; Fiscal Year: 2009..Immunohistochemistry, detection of plasminogen activator and MAPK expression, and CBF determination by radiolabled microspheres will be performed. ..
- Plasminogen activators and NMDA after brain injuryWilliam M Armstead; Fiscal Year: 2010..Immunohistochemistry, detection of plasminogen activator and MAPK expression, and CBF determination by radiolabled microspheres will be performed. ..
- POTASSIUM CHANNELS AND CEREBRAL HEMODYNAMICS AFTER BRAINWilliam Armstead; Fiscal Year: 2005..These studies may lead to therapies for brain injured children. ..
- Plasminogen activators and cerebral ischemic injuryWilliam M Armstead; Fiscal Year: 2010....
- Plasminogen activators and cerebral ischemic injuryWilliam Armstead; Fiscal Year: 2007....
- PATHOGENESIS OF TRANSPLANT ASSOCIATED ARTERIOSCLEROSISPeter Libby; Fiscal Year: 2002..The observations point to distinct mechanisms mediating acute vs. chronic allograft pathologies, and suggest that different therapeutic interventions will be uniquely applicable to each. ..
- REDUCTION OF TRIGLYCERIDES IN WOMEN ON HRTLewis Kuller; Fiscal Year: 2005..NMR spectroscopy of lipoproteins, inflammatory markers, and estrogen metabolites will also be evaluated. Therefore, the primary goal of this trial is the modification of measures of subclinical disease among HRT users. ..
- EPIDEMIOLOGY OF CARDIOVASCULAR RISK FACTORS IN WOMENLewis Kuller; Fiscal Year: 2002..They further note that the identification of early and modifiable risk factors for subclinical disease should lead to prevention or reduction of clinical cardiovascular disease among postmenopausal women. ..
- Cytokines and Sympathetic Activation in Heart FailureRobert Felder; Fiscal Year: 2006..These studies will provide new insights into the role of the pro-imflammatory cytokines in heart failure, perhaps leading to new therapeutic strategies. ..
- Northeast Ohio Center for Cardiovascular Cell Therapy ResearchStephen Ellis; Fiscal Year: 2007..End of Abstract) ..